On July 24-28, 2022, local time, the 74th AACC Annual Scientific Meeting & clinical lab Expo was grandly opened in Chicago. Ameson brought cancer early screening products to the exhibition site to show the world the charm of China's national brand and cutting-edge technology.
AACC is the world's largest in vitro diagnostic industry conference. Since 1950, it has become one of the highest quality and largest international academic conferences in the field of clinical testing in the world, with important international influence. According to the official website of AACC, there are 819 exhibitors from more than 100 countries and regions in the world.
△ 本届AACC在芝加哥迈考密展览中心盛大开幕
△Ameson brings cancer early screening products to AACC
In this grand meeting, among the self-developed products carried by Ameson, aichangkang ® It has obtained the national class 3 medical device registration certification, and is the first product in China based on the double label detection of intestinal cancer. The detection can take into account different parts of the large intestine. The detection sensitivity for intestinal cancer is 95.3%, and the detection rate for precancerous lesions is 63.4%. The performance is excellent. In 2021, the detection products of colorectal cancer were recognized as 'international advanced level' by the Ministry of industry and information technology. And 7 products have obtained CE certification, including: colorectal cancer fecal DNA methylation detection kit - aichangkang ®， Blood methylation detection kit for colorectal cancer AI Changjian ®， Esophageal cancer blood methylation detection kit - aisinin ®， Liver cancer blood methylation detection kit - aixingan ®， Cervical cancer methylation detection kit - aigongshu ®， Detection kit for methylation of exfoliated cells of endometrial carcinoma -- aigongle ®， Aixiao'an, a blood methylation kit for joint detection of five cancers in digestive system ® And a series of early non-invasive detection products for high-risk tumors.
△Early screening and early diagnosis scheme for intestinal cancer by Ameson - AI Changkang ®
△The amison booth attracted many participants
Adhering to the corporate mission of 'early screening of cancer and victory over cancer', amison has demonstrated its determination and vision to build a community with a shared future for human health and free hundreds of millions of families around the world from the pain of cancer. We will base ourselves on our own land, look at the world, continue to innovate, and show the world the strength of China's independent research and development and the strength of China's brand.
About amison Life Technology
武汉艾米森生命科技有限公司成立于2015年1月，是一家专注于全球高发恶性肿瘤早期无创检测产品研发、注册、生产及销售的高新技术企业，公司致力于癌症早诊技术和产品的全球化推广，结合表观遗传学、生物信息学、临床大数据和人工智能分析，秉持“早期、精准、便捷、普惠”的产品理念，开创构建了新一代肿瘤筛查检测技术平台和产品体系，领先推出了涵盖消化系统肿瘤、妇科肿瘤、泌尿系统肿瘤与泛癌种等一系列高发肿瘤的早期无创检测产品，真正实现了肿瘤早期、无创、精准检测，从根本上降低了肿瘤的发病率和死亡率，将癌症扼杀于萌芽，为人类生命健康保驾护航。
Focus on the needs of diagnosis and treatment
Take striving innovators as the fundamental